Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on January 18, 2013, covering events occurring on January 16 and January 17, 2013. The filing addresses corporate governance updates regarding director indemnification and executive compensation adjustments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on legal agreements and personnel compensation rather than financial performance results.
Material Changes
- Indemnity Agreements: The Board approved a modification to the form of indemnity agreement for directors and senior officers, effective January 17, 2013. This amendment broadens the scope of indemnifiable expenses and supersedes existing agreements.
- Executive Compensation: On January 16, 2013, the Compensation Committee approved changes to the compensation package for Robert G. Kramer, Executive Vice President and CFO, effective January 1, 2013.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary focus is on the specific terms of the new indemnity agreement and the updated severance and salary structure for the CFO.
Key Facts for Investor Verification
- CFO Compensation: Robert G. Kramer's 2013 annualized base salary is set at $430,000 with a target bonus of 50%.
- Severance Terms: Mr. Kramer's severance benefits are 125% of salary for 15 months (standard termination) and 200% of salary for 24 months (change in control termination).
- Legal Exposure: Verify the specific language in the amended Form of Indemnity Agreement (Exhibit 10) to understand the expanded scope of indemnifiable expenses for directors and officers.